Company

Bank

Analyst

Coverage

Opinion

Wk chg

1/17 cls

AMAG Pharmaceuticals Inc. (NASDAQ:AMAG)

Jefferies

Eun Yang

Upgrade

Hold (from underperform)

-3%

$21.01

Ladenburg Thalmann

Juan Sanchez

Downgrade

Neutral (from buy)

Yang also raised her target to $19 from $16 despite FDA's complete response letter for an sNDA to expand the label of Feraheme ferumoxytol to include treatment of all adults with iron deficiency anemia who have failed or could not tolerate oral iron treatment (see B16). She sees upside from the potential acquisition of products using AMAG's current cash of about $210M and/or the potential approval of the drug's broader indication in the EU, triggering a milestone payment from partner Takeda Pharmaceutical Co. Ltd. (Tokyo:4502). Feraheme, known as Rienso in the EU, is already approved to treat iron deficiency anemia in adults with chronic kidney disease (CKD).